177 Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials.

Alberto BongiovanniSilvia NicoliniToni Ibrahim Flavia FocaMaddalena SansoviniArianna Di PaoloIlaria GrassiChiara LiveraniChiara Calabrese Nicoletta Ranallo Federica MatteucciGiovanni PaganelliStefano Severi

Published in: Cancers (2022)

The 177 Lu-DOTATATE improved symptoms and disease control in patients with F-NETs. Treatment was well tolerated. The syndrome had an impact on both quality of life and OS.

Keyphrases

neuroendocrine tumors
phase ii
clinical trial
open label
pet ct
phase iii
double blind
placebo controlled
study protocol
depressive symptoms
physical activity
sleep quality